Monday, November 2, 2026

Back to today

BMRN Earnings Review

BioMarin’s Q3 revenue rose 32% to $1.02 billion after the Amicus acquisition, while lower 2026 guidance and $2.8 billion of net debt weighed on earnings.

From X

@ParadisLabs

Paradis on X

Personal dip buys from today: $AVGO, $MRVL, $KLAC $AVGO: - Feels like the market has overlooked Broadcom YTD. - I think they're still one of the best positioned in the networking theme thanks to exposure to many diverse areas - optical DSP, Tomahawk, Jericho. - Future growth should accelerate via Tomahawk 6/7 ramping in 2027, Tomahawk Ultra, optical DSPs. - Obviously there are risks with Broadcom but I ultimately see earnings upside = stock should re-rate (at some point lol). $MRVL: - Investor day last week basically confirmed that they're a scaleable AI infra name...not just custom silicon / DSP. - Feels like Marvell's opportunity is now much bigger than most people thought. - E.g. other than 800G/1.6T....NPO/CPO, and scale-out + up. - Still think it's early from them with many areas yet to ramp volumes e.g. 1.6T and NPO/CPO. Overall, feels like both Broadcom and Marvell are very well positioned. Broadcom keep adding XPU customers + extend those deals with hyperscalers. Marvell keep growing, very high torque right now IMO. $KLAC: - Down 42% in 3.5 months and haven't had a position before and wanted to take one lol - more so as a re-rating trade rather than a longer-term hold. - No real in depth thesis, more so a risk/reward play in the broader "AI quality" ecosystem I'm tracking. - Especially when compared against other semicaps like $LRCX / $AMAT that are well ahead in YTD %. Obviously these aren't your sexy names like $NBIS, $INTC or $BE - but I feel like I built my positions in these types of names earlier in the year (was a little late to the Intel party) and don't want my core portfolio to get overly concentrated. That said, I'm well aware that semis earnings are right around the corner and that many of these bottleneck type names have de-rated. But as of right now, I'm sitting slightly on the cautious side by not attempting to time bottoms here. Recent flow data has been tragic for semis, so would rather wait to see a few days of +ve net flows first to get some confidence that investor fatique isn't a permanent scar. There's only so much tolerance investors have for multiple >20% drawdowns in a matter of months.

Altria: Dutiful

Altria raised 2026 adjusted EPS guidance to $5.66 to $5.74 and authorized more buybacks, while on! loses share as cigarette margins hold.

BR · long

Broadridge Financial Solutns

Broadridge Financial Solutions is framed as a high and rising free-cash-flow generator at a depressed valuation, with insider buying…

FTAI 3Q26: Aero margins in focus

FTAI’s Aerospace Products margin rebounded to 31% as CFM56 module output rose, while Power deposits and contracted deliveries fund its 2027…

CVX Earnings Review

Chevron’s Q3 revenue rose 35% to $65.2 billion and EBITDA 75% to $20.2 billion, while production trailed guidance and refining margins…

SNY Earnings Review

Sanofi raised FY26 guidance after Q3 sales grew 14.3% at constant currency, led by 34.8% Dupixent growth; vaccines declined 6.6%.

TSOH Weekly Roundup (10/30/2026)

Markel spent $315 million repurchasing shares in Q3 as Thrive agreed to buy ADT for $7.6 billion and Hasbro cited rising adult toy demand.

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

X accounts we follow

Every account on this site, hand-picked.

91 accounts

Investor letters we follow

303 firms

Sectors

Ordered by how often our editor reaches for them.